Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT06073821
Trial Phases:	Phase III	Protocol IDs:	BGB-11417-301 (primary) NCI-2023-09813
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	BeiGene
NCI Full Details:	http://clinicaltrials.gov/show/NCT06073821

Summary

The main objective of this study is to compare the efficacy of sonrotoclax plus
zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic
leukemia (CLL)

Objectives

Chronic lymphocytic leukemia is a type of blood cancer that affects people around the
world. People with CLL suffer from enlarged lymph nodes, spleen, or liver, or have
symptoms like night sweats, weight loss and fever. They have shorter life expectancy
compared to healthy people. There is an urgent need for new treatment to prolong
participant life and control disease-related symptoms.

In this study, participants with CLL, without prior treatment will receive either
venetoclax plus obinutuzumab combination treatment that is considered a standard first
line treatment or receive sonrotoclax plus zanubrutinib. It is hypothesized that
sonrotoclax plus zanubrutinib may be better than venetoclax plus obinutuzumab in treating
CLL.

The main purpose of this study is to compare the duration the participants live without
the CLL getting worse between participants who received venetoclax plus obinutuzumab
versus sonrotoclax plus zanubrutinib. Approximately 640 participants will be included in
this study around the world. Participants will have equal chance to be allocated to
receive either of the treatment combinations.

Treatment Sites in Georgia

City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.